Ranbaxy Receives Approval to Market RAN(R)-Lisinopril in Canada



    TORONTO, Oct. 22 /CNW/ -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a
wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today
that RLL has received approval in Canada to manufacture and market
RAN(R)-Lisinopril 5, 10 and 20 mg oral tablets from Health Canada, Therapeutic
Products Directorate (TPD).  Total brand market for Lisinopril 5, 10, and 20
mg oral tablets in Canada is CAD $46 mil. (IMS-MAT: August 2007).
    Lisinopril is indicated for the treatment of hypertension and may be used
alone as initial therapy or concomitantly with other classes of
antihypertensive agents, and as adjunctive therapy in the management of heart
failure in patients who are not responding adequately to diuretics and
digitalis, as well as in the treatment of hemodynamically stable patients
within 24 hours of acute myocardial infarction, to improve survival.
    "We are pleased to receive this approval for RAN(R)-Lisinopril to expand
Ranbaxy's product portfolio of accessible generic product offerings.  The
product formulation was developed and data assembled by RLL. RAN(R)-Lisinopril
will be manufactured in Ranbaxy's cGMP facility located in North Brunswick,
New Jersey.  RPCI's Sales Team will be offering product to all classes of
trade in all of the Canadian provinces immediately," said Paul Drake,
President, RPCI.
    Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario,
Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL),
India's largest pharmaceutical company.  RPCI is engaged in the sale and
distribution of generic prescription products in the Canadian healthcare
system.
    Ranbaxy Laboratories Limited, headquartered in India, is an integrated,
research based, international pharmaceutical company producing a wide range of
quality, affordable generic medicines, trusted by healthcare professionals and
patients across geographies. Ranbaxy's continued focus on R&D has resulted in
several approvals in developed markets and significant progress in New Drug
Discovery Research. The Company's foray into Novel Drug Delivery Systems has
led to proprietary "platform technologies", resulting in a number of products
under development.  The Company is serving its customers in over 125 countries
and has an expanding international portfolio of affiliates, joint ventures and
alliances, ground operations in 49 countries and manufacturing operations in
11 countries.

    
    CONTACTS: Charles M. Caprariello
              Vice President,Corporate Communications
              Ranbaxy Inc.
              (609) 720-5615
    

    
              Paul Drake
              President and General Manager
              Ranbaxy Pharmaceuticals Canada, Inc.
              (905) 219-8820
    




For further information:

For further information: Charles M. Caprariello, Vice
President,Corporate  Communications, Ranbaxy Inc. 609-720-5615; Paul Drake,
President and General  Manager, Ranbaxy Pharmaceuticals Canada, Inc.,
905-219-8820

Organization Profile

RANBAXY LABORATORIES LIMITED

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890